Li, 18 patient bromhexine early treatment RCT: 75% higher hospital discharge [p=0.11] and 3% slower recovery https://c19p.org/li5
copied to clipboard
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
et al., Clinical and Translational Science, doi:10.1111/cts.12881
Tiny RCT with 12 bromhexine and 6 control patients showing non-statistically significant improvements in chest CT, need for oxygen therapy, and discharge rate within 20 days. Authors recommend a larger scale trial.Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
|
risk of no hospital discharge, 75.0% lower, RR 0.25, p = 0.11, treatment 2 of 12 (16.7%), control 4 of 6 (66.7%), NNT 2.0.
|
|
risk of oxygen therapy, 50.0% lower, RR 0.50, p = 0.57, treatment 2 of 12 (16.7%), control 2 of 6 (33.3%), NNT 6.0.
|
|
recovery time, 3.2% higher, relative time 1.03, treatment 12, control 6.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Li et al., 9/3/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 10 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.